Abcam, ab227815, Anti-CDA antibody [EPR20525] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal CDA antibody. Carrier free. Suitable for WB, Flow Cyt (Intra), IHC-P and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR20525,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:Flow Cyt (Intra), IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab227815 is the carrier-free version of
ab222515
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Cytidine deaminase (CDA) also known as CDD is a zinc-dependent enzyme responsible for deaminating cytidine. The full form of CDA has a molecular mass of approximately 41 kDa. CDA is widely expressed in various tissues including liver kidney and leukocytes. It plays an important role in nucleotide metabolism by converting cytidine to uridine and 2'-deoxycytidine to 2'-deoxyuridine which impacts nucleic acid stability and synthesis. Researchers frequently use techniques such as ELISA and Western blotting to study CDA expression and activity often referencing it in contexts like "CDA Western" or "57 seconds CDA."
Biological function summary
CDA enzyme influences the pyrimidine salvage pathway by facilitating nucleotide degradation and recycling. It operates independently rather than as part of a protein complex. The activity of this enzyme ensures a balanced nucleotide pool essential for DNA replication and repair processes. This balance affects cellular proliferation and survival highlighting the importance of studying CDA protein in normal physiology and various pathological conditions.
Pathways
CDA contributes significantly to pyrimidine metabolism and its recycling pathway. It maintains a connection with ribonucleotide reductase which plays a role in the regulation of deoxyribonucleotide pools during DNA synthesis. This interplay highlights the enzyme’s involvement in DNA repair pathways ensuring proper cell division and genomic integrity. Within these pathways enzymes like cytidine triphosphate synthetase also relate to CDA by participating in nucleotide homeostasis.
Improper CDA function is linked to specific cancers including acute myeloid leukemia due to altered nucleotide metabolism leading to genomic instability. The enzyme's activity also affects the pharmacokinetics of cytidine analogues like gemcitabine used in cancer treatment. CDA overexpression might result in reduced drug efficacy thereby hindering therapy in affected patients. Connections exist between CDA and proteins involved in chemoresistance such as ribonucleotide reductase showing its significance in treatment outcomes.